Re-evaluating the role of FOXOs in cancer

Publication date

2018-06

Authors

Hornsveld, M
Dansen, TobiasORCID 0000-0001-5259-8815ISNI 0000000394902015
Derksen, PatrickORCID 0000-0003-0732-7762ISNI 0000000392612647
Burgering, BoudewijnORCID 0000-0002-4044-9596ISNI 0000000391409962

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc_nd

Abstract

FOXO transcription factors are negatively regulated by the PI3K-PKB/AKT signaling pathway and have been mainly considered to be tumor suppressors due to their inhibitory effect on cancer cell growth and survival. However, FOXOs can also support tumor development and progression by maintaining cellular homeostasis, facilitating metastasis and inducing therapy resistance. In agreement with these opposing views on the role of FOXOs in cancer, studies using FOXO levels or activity as prognostic markers for cancer patient disease progression and survival came to contradicting results. While it is clear that FOXOs are involved in various aspects of cancer, it is debatable whether FOXOs function as tumor suppressors or supporters, or may be both depending on the context. In this review, we describe the role of FOXOs in signaling pathways and processes relevant to cancer and evaluate recent advances in understanding the role of FOXOs in cancer. Based on recent insights it becomes clear that FOXOs may not be classical tumor suppressors and that targeting FOXO activity might hold promise in cancer therapy.

Keywords

Cancer therapy, FOXO, PI3K, PKB/AKT, Signal transduction, Tumor suppressor, Tumorigenesis, Cancer Research

Citation

Hornsveld, M, Dansen, T B, Derksen, P W & Burgering, B M T 2018, 'Re-evaluating the role of FOXOs in cancer', Seminars in Cancer Biology, vol. 50, pp. 90-100. https://doi.org/10.1016/j.semcancer.2017.11.017